18 FEBRUARY 2026

ASX RELEASE

CONFERENCE PRESENTATION

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX; OTCQB:INNMF), ("Amplia" or the "Company") announces that Amplia's COO Dr Rhiannon Jones is presenting today at the Emergence 2026 conference, being held in Sydney, NSW, Australia. The presentation outlines recent progress from the Company's ACCENT clinical trial in pancreatic cancer and outlines forthcoming development milestones.

A copy of the presentation is attached to this announcement.

This ASX announcement was approved and authorised for release by the CEO.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

U.S. Contact:
Robert Giordano
rjgiordano@ggrouplifesciences.com

+1 917 327 3938

Media Contact:

H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

U.S. Media:
media@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary

fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently being investigated in two clinical trials in pancreatic cancer. The most advanced clinical trial (ACCENT) investigates a combination with the chemotherapies gemcitabine and Abraxane® in first-line patients with advanced pancreatic cancer. The trial has already achieved its primary endpoint in achieving a confirmed response rate of 35%, superior to 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. An interim median PFS of 7.7 months has also been reported.

A second trial – AMPLICITY – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.

Amplia THERAPEUTICS

TARGETING PANCREATIC CANCER AND BEYOND

February 2026

ampliatx.com | @ampliatx
ASX: ATX | OTCQB: INNMF

DISCLAIMER

This presentation (**Presentation**) contains summary information about Amplia Therapeutics Limited ACN 165 160 841 and its subsidiaries (the **Company** or **Amplia**) which is current as at 31 December 2025. By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below.

Summary Information: This Presentation has been prepared for information purposes only and is a summary only. It should be read in conjunction with Amplia's most recent financial report and other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which is available at www.asx.com.au. Subject only to any legal obligation to do so, the Company does not have any obligation to correct or update the content of this Presentation.

Not financial product advice: This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon as such. This Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (or any other law). It is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.

Investment risk and past performance: An investment in Amplia shares is subject to known and unknown risks, some of which are beyond the control of the Company and its directors. The Company does not guarantee any particular rate of return or the performance of Amplia. Past performance is not, and should not be relied on as being, indicative of future performance.

Future performance and forward-looking statements: This Presentation includes forward looking statements, which can generally be identified by the use of words such as "may", "will", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. They may include, without limitation, statements regarding plans, strategies and objectives and anticipated business developments. Forward-looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause Amplia's actual results, performance and achievements to differ materially from statements in this Presentation. Forward-looking statements are based on the Company's good faith assumptions as to the financial, market, regulatory and other relevant environments that will exist and affect Amplia's business and operations in the future. The Company does not give any assurance that the assumptions will prove to be correct. There may be other factors that could cause actual results or events not to be as anticipated, and many events are beyond the reasonable control of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements in this Presentation are only made as at the date of this Presentation and the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

Industry data and third party information: Industry data and third party information used in this Presentation may have been obtained from research, surveys, reports or studies conducted by third parties, including industry or general publications. Neither Amplia not its representatives have independently verified any such market or industry data.

Financial Information: This Presentation contains historical financial information based on the Company's results for the 12 month period ending 31 December 2025 and management accounts to 31 December 2025. All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding.

Disclaimer: To the maximum extent permitted by law, Amplia and its officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Amplia or that a prospective investor or purchaser may require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any forward-looking statement.

PANCREATIC CANCER

A devastating disease with limited treatment options





3%
chance of surviving >5 years with metastatic disease

80%
of pancreatic cancers diagnosed at stage 3 or 4



A FIBROTIC SHIELD

Amplifying existing cancer treatments by reducing the fibrotic barrier that makes cancers difficult to treat



Cancer Associated Fibroblasts produce a dense fibrous matrix that surrounds the tumour and creates a barrier for chemotherapy

Narmafotinib acts to reduce the fibrous tissue thus allowing chemotherapy and other treatments to penetrate

Both narmafotinib and the chemotherapy can act directly on the cancer cells to kill them

THE ACCENT TRIAL

Improving treatment options for metastatic pancreatic cancer

Confirmed Overall Response



Progression Free Survival



Safety



Compared to the MPACT Study (2013)

PETER'S STORY

An amazing outcome for a dreadful disease

Peter's pancreatic marvel: meet the luckiest man in the country

EXCLUSIVE

Test results stunned doctors in Australia ... and across the world

NATASHA ROBINSON
HEALTH EDITOR

Peter Moulding was recovering from surgery when his oncologist received the Melbourne tradie's pathology results – and the doctor couldn't believe his eyes.

"I actually called the pathologist and said: Are you sure you're looking at the right specimen?" says Prasad Cooray, an oncologist at the Jeffrissati Pancreatic Centre at the Epworth Hospital in Melbourne.

"Because I think all of us had difficulty believing this was true."

The tissue specimens were small slices of what had appeared as "shadows" on medical imaging of Mr Moulding's pancreas. Clinicians had performed tumour resection surgery of these suspect tissues 12 months after Mr Moulding, a metastatic pancreatic cancer patient, had been signed up to a clinical trial testing a novel drug. But the shadow tissue was not cancer at all.

Mr Moulding is in remission from metastatic pancreatic cancer, having experienced what is known in medicine as a pathological complete response to treatment. This means that cancer is no longer detectable. This is vanishingly rare in metastatic pancreatic cancer, so rare that Dr Cooray is confident no oncologist in Australia he's in touch with has ever seen such a phenomenon. In the scientific literature, doctors believe only one other case of a pathological complete response in a metastatic cancer patient has been recorded worldwide.

"I've never come across a case like Peter's where there is no residual cancer left," Dr Cooray says. "So this is a highly, highly unusual finding."

'Groundbreaking'

Mr Moulding was part of a clinical trial of a drug developed in Australia known as narmafotinib, or AMP945, which has the potential to make chemotherapy much more effective because it breaks down a fibrous shield that surrounds cancer cells, making them difficult to penetrate.

This fibrous shield builds up around pancreatic cancer tumours largely owing to a protein known as focal adhesion kinase, which forms a protective environment around tumours that stops chemotherapy from reaching tumours. FAK can also act as a "survival switch" for cancer cells, switching on the activity of the FAK protein, which also contributes to the formation of the fibrous protective layer around tumours. AMP945 may be able to turn off that switch, making the cancer cells easier to kill.

When Mr Moulding, a refrigeration mechanic from outer western Melbourne, was given the opportunity to join the trial testing AMP945, he jumped at it. At the time, he didn't know the prognosis for pancreatic cancer patients was devastatingly poor. Only one in five of all patients is alive 12 months after diagnosis.

"I didn't know what stage four was, and I didn't ask," Mr Moulding says. "I just went along for the ride, basically. I just thought, well, I'll do what I've got to do, and hopefully they'll operate and fix it for me."

In fact, surgery for metastatic cancer patients – where the cancer has spread to other parts of the body – usually does not happen. Currently, the best these patients can hope for is that chemotherapy prolongs their life.

"In the pancreatic cancer space there really hasn't been any significant development in treatment for decades," Dr Cooray says. "Yes, there's been some improvement in chemotherapy drugs, but a drug that looks at the cancer from a different angle has not happened in pancreas cancer ever. So if this drug proves to be effective, this will be a groundbreaking development in pancreatic cancer."

AMP945 was developed by Amplia Therapeutics under the umbrella of Australia's Cancer Therapeutics Co-operative Research Centre – set up by the federal government in 2007 to bridge the gap between research breakthroughs and commercialisation – in conjunction with scientists from the nation's top universities and scientific institutes. The Garvan Institute of Medical Research has previously established that targeting FAK prior to treatment makes pancreatic cancer cells more sensitive to chemotherapy and reduces cancer spread by 50 per cent in mice. The drug has been shown in early studies to also have application for ovarian cancer, which also involves fibrosis.

Reason for hope

Despite the promising results in animal studies, Amplia chief executive Chris Burns said the results of the human trial so far have exceeded his company's expectations.

"To see a pathological complete response was totally unexpected. We never thought it would happen," Dr Burns says.

He says the majority of patients in the trial have had more tumour shrinkage than would have been expected with chemotherapy alone. "This is entirely consistent with breaking down that fibrotic tissue and allowing the drug to penetrate and work better," he says. "So we definitely have an indication that the fibrosis is breaking down.

"We were hoping that we could extend survival significantly, but where we see the kind of level of response that we've seen, because it's so new, we don't know what that might mean longer term. Potentially it's transformative, we could actually totally change the trajectory of this disease.

"It definitely gives patients hope that there is progress being made, that rather than pancreatic cancer being a death sentence, I would hope that we're looking at the beginning of a change that means this cancer might be a manageable disease in a few years' time."

The clinical trial for AMP945, known as the ACCENT trial, is in phase two safety and efficacy testing. Full phase two results will be analysed and will be published in about six months, and an international phase three study will follow.

As well as Mr Moulding's stunning response, one other patient in the trial has also had a complete response to treatment, meaning the disappearance of all tumour lesions that is maintained for at least 2 months. Sixteen other patients have had a partial response, where tumour shrinkage greater than 30 per cent is recorded and sustained for two or more months and where no new cancerous lesions have been detected. About 50 people in Australia and Korea were initially signed up to the trial 18 months ago, and there are 20 still remaining on the drug treatment, which is given for about four days prior to monthly rounds of chemotherapy.

No other patients have had such a stunning response as Mr Moulding, but Dr Cooray, who is planning to write up Mr Moulding's case for a scientific journal, says his observation is that most of the patients in the trial have done better than had they received standard treatment.

"We don't have the data published yet, so I don't want to be speaking prematurely but, at the same time, I don't want to dial down the excitement that goes with this pathological complete response, either. Every win we need to celebrate," he says. "This being the first pathological complete response is highly significant. I can definitely say that much. And in my career of close to 20 years, this is the first time I've come across that. And the only added variable in this case was the drug, the FAK inhibitor.

"I'm not saying all pancreatic patients will benefit from this drug. We know from other cancer types, when a targeted treatment works, there's some subgroup where it is more effective than in others ... that is part of the puzzle."

Making plans

Allan Zimet, a medical oncologist at the Jeffrissati Pancreatic Centre, says Mr Moulding's case and that of other patients whose tumours have significantly shrunk may provide important clues as to why some patients respond to AMP945 and others don't.

Pancreatic cancer patients often have in their DNA what is known as KRAS mutations, which drive tumour mutation and progression. These mutations have been considered undruggable, but that may not be true.

"We're now in the era of personalised medicine," Dr Zimet says. "Genetic mutations may be driving the fibrosis in pancreatic cancer patients, and if you target the mutation and switch off the fibrosis, you may be able to improve the patient's outcome.

"This drug is still very much investigational, and so it's a potential pointer that this may be a good drug that may have particular activity, but it's a pointer at this stage. It's not a sort of 'lay-down misere'. It's important people understand and that we don't raise false hopes.

"But pancreatic cancer has been an orphan cancer in many ways, because people have been nihilistic about the effects of treatment. There are not many patient advocates, because our patients are too unwell for that, and their survival is not good enough for them to be involved. "So I think that a good news story like this will only help to stimulate medical research efforts further, and to look and to review and see what's special about this person who has had such a good response, and how we can we learn some deeper lessons from this."

As for Mr Moulding, the hard-working tradie has realised he has no time to waste. He has worked as a small-business owner all of his life and always intended to put off travel and taking time out until retirement. But he is now fast-tracking his plans.

"I just want to do some things that are going to make me happy and enjoy what I've got left of my time, I suppose," he says. "It would be nice to actually get off my bum and do some travelling."

As patient zero, Mr Moulding has immense gratitude for the being part of the clinical trial. "I don't know really what to say except that I'm just so happy," he says. "I was given the opportunity to have a go of it, and it's actually worked."

Confirmed Partial Response

Surgery to remove remaining tumour and metastases

No live tumour cells detected in removed tissue

Pathological Complete Response

OPPORTUNITIES

Overcoming other difficult-to-treat cancers



KEY MILESTONES

Upcoming events



A RECORD OF SUCCESS

The team to progress this project

Developed drugs that have made it to market

Broad experience from leading pharma and biotech companies

Bristol Myers Squibb®

gsk

Pfizer

Medicines Development for Global Health

zoetis

cytopia
DEVELOPING BETTER DRUGS

receptos

PolyActiva

mesoblast

Cancer Therapeutics CRC

Amplia THERAPEUTICS

THANK YOU

Chris Burns PhD GAICD FAHMS
CEO and MD

chris@ampliatx.com

Rhiannon Jones PhD GAICD
COO

rhiannon@ampliatx.com

Amplia Therapeutics Limited
ASX: ATX | OTCQB: INNMF
info@ampliatx.com

ampliatx.com